Glomerulonephritis (GN) is a rare kidney disease that can lead to increased morbidity and End-stage kidney disease. Most nephrologists have limited exposure in dealing with complex GN patients. Recently, in last three years, there have been many new medications that have received FDA approval for managing these patients. There is still uncertainty with respect to which patients would be ideal for newer medications and how to balance risk-benefit ratio. Main goal of this symposium would be to discuss updates in management of GNs with emphasis on practical approach for patient care.